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Summary
QUESTIONS UNDER STUDY: We investigated non-
malignancy-associated (18F)fluoro-deoxy-D-glucose
(FDG) uptake in the head and neck cancer (HNC) post-
treatment follow-up with positron emission tomography
– computed tomography / magnetic resonance imaging
(PET-CT/MRI). A retrospective study on HNC patients un-
dergoing follow-up or re-staging PET-CT/MRI examina-
tions was performed. Thereby, FDG-positive regions were
morphologically correlated to the CT and MRI images and
a statement regarding tumour persistence/recurrence.
METHODS: FDG-positive lesions were assessed accord-
ing to their anatomical localisation and categorised as true
positive, true negative, false positive or false negative find-
ings. The gold standard for verification of an FDG-positive
lesion was the cytological or histopathological examination
of the region of interest. The most likely aetiology was as-
sessed according to the following categories: (1.) physiolo-
gical uptake (2.) post-surgical, inflammatory uptake, (3.)
post-irradiation, inflammatory uptake and (4.) reactive, not
otherwise specified.
RESULTS: Tumour recurrence / tumour persistence was
found in 14/87 patients (16.1%). A total of 159 non-
malignancy-associated FDG-positive lesions were found.
Every PET-CT/MRI examination revealed 2.1 ± 1.5 FDG-
positive lesions in the head and neck. A total of 107 FDG-
positive lesions (67.3%) were categorised as physiological,
52 FDG-positive lesions (32.7%) as inflammatory (post-
surgical: n = 14, 8.8%; post-irradiation: n = 9, 5.7%; react-
ive, not otherwise specified: n = 29, 18.2%). Eight patients
(11.8%) underwent invasive diagnostic procedures to clari-
fy indistinct findings.
CONCLUSIONS: Post-treatment follow-up of HNC pa-
tients requires interdisciplinary management and famili-
arity with the patient’s past medical history. Awareness
of common confounders of FDG positivity often allows
clarification of indistinct lesions. However, a substantial
number of approximately 12% of FDG-positive lesions re-
main unclear unless invasive diagnostic procedures are per-
formed.
Key words: head and neck cancer; post-treatment
surveillance; FDG PET-CT; FDG PET-MRI; pitfalls
Introduction
Post-treatment surveillance of head and neck cancer (HNC)
requires periodic clinical and radiological examinations to
exclude persistence or recurrence of locoregional disease,
distant metastases or secondary tumours. Despite aggress-
ive multimodal therapy regimens, locoregional recurrence
appears in up to 40%, whereby most recurrences occur
within the first 2 years after primary treatment [1–3]. In
recent years, (18F)fluoro-deoxy-D-glucose (FDG) positron
emission tomography (PET) – computed tomography (CT)
has become a valuable tool in post-treatment surveillance,
which provides information on the metabolic activity and
the anatomical localisation of the locoregional tumour site
and therefore is superior in certain cases to conventional
imaging modalities, such as PET, CT or magnetic reson-
ance imaging (MRI) [4–7]. This is especially true for PET-
negative conditions, since the negative predictive value
has been demonstrated to be consistently high (>90%) and
therefore negative periodic clinical examinations may be
complemented by PET-CT [8]. However, there are various
non-malignant FDG-positive conditions, which may cause
increased FDG uptake, resulting in a positive predictive
value (PPV) of only 64–77% in detecting locoregional per-
sistence or recurrence [8, 9]. Being confronted with this
high number of false-positive results, interpretation of
PET-CT is challenging and can result in potentially un-
necessary investigations, interventions and patient uncer-
tainty. With the recent introduction of PET-MRI, several of
those challenging cases in PET-CT might be solved on the
basis of the unmatched soft tissue contrast and partly less
susceptibility to dental artefacts [10–12].
The aim of this study was to support treating physicians
by providing typical distribution patterns and aetiologies
of non-malignancy-associated FDG-uptake in the PET-CT/
MRI post-treatment follow-up of HNC.
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Material and methods
Patient population
A retrospective study was performed involving consecutive
HNC patients undergoing follow-up or re-staging PET-CT/
MRI between February 2012 und February 2013. All pa-
tients were discussed in our multidisciplinary tumour board
and staged according to the latest version of the American
Joint Committee on Cancer (AJCC) guidelines [13]. Pa-
tients were initially treated with curative intent for primary
tumours and had accomplished individual treatment proto-
cols, including surgery and/or radiation therapy (RT) and/
or chemotherapy. As part of the post-treatment follow-up
programme, patients with a large primary tumour (>T2)
and / or multiple regional metastases (>N2a) underwent
periodic clinical examinations and PET-CT/MRI examina-
tions at 3, 9 and 18 months post-treatment. Patients with
clinically suspected tumour recurrence or persistence after
primary therapy received either cyto-/histopathological ex-
aminations or further clinical and imaging examinations
within shorter time periods.
Imaging
Sequential PET-CT/MRIs (with intravenous contrast media
applied in head and neck MRI and PET-CT) were per-
formed on a tri-modality PET-CT/MRI setup (full ring,
time-of-flight Discovery PET-CT 690, 3T Discovery MR
750w, both GE Healthcare, Waukesha, WI, USA). For de-
tailed imaging protocols and imaging processing we refer
to our previously published paper [11].
Clinical evaluation
Patients’ charts were reviewed for demographic data and
tumour characteristics [13], and the patients underwent a
clinical examination. Treatment protocols were analysed
for surgical resection of the primary tumour, free tissue
transfer/local flaps, neck dissection (unilateral vs bilateral),
radiation therapy (RT) (unilateral vs bilateral) and chemo-
therapy. Furthermore, the length of the post-treatment peri-
od was assessed.
Statistical analysis
All PET-CT/MRI examinations were reviewed by one dual
board-certified radiologist / nuclear medicine physician
and one otorhinolaryngology (ENT) surgeon. FDG-posit-
ive lesions in the head and neck were assessed according
to their anatomical localisation. FDG-positive lesions were
graded as true positive, true negative, false positive or false
negative, on the basis of further clinical, cytological, his-
tological or ultrasound examinations. The most likely ae-
tiology of FDG positive lesions was categorised as: (1.)
physiological uptake (e.g. muscle activity), (2.) post-sur-
gical, inflammatory uptake, (3.) post-irradiation, inflam-
matory uptake and (4.) reactive, not otherwise specified,
inflammatory uptake [14]. In the case of uncertainty re-
garding the aetiology of a FDG-positive lesion, corres-
ponding MRI examinations were used for better soft-tissue
contrast. Of note, for a systematic comparison of PET-CT
versus PET-MRI we refer to a previously published study
by our group [11]. The gold standard for verification of
indistinct FDG-positive lesions was cytological or histo-
pathological examination. Data were expressed as mean ±
standard deviation (SD) or median and interquartile range
(IQR) if appropriate. Descriptive statistics were made using
SPSS for Windows 15.0 (SPSS, Inc., Chicago, IL, USA).
Results
Demographic data
In summary, 87 patients were included in this study: 68
male patients (78.2%) vs 19 female patients (21.8%). At
the time of PET-CT/MRI examination, the mean age of all
Table 1: Patient and tumour characteristics for all 87 patients
included.
Age at FDG PET/CT-MRI scan:
Mean ± SD (years) 63.2 ± 12.0
Range 24–90
Gender:
Male 68 (78.2%)
Female 19 (21.8%)
Primary tumour site:
Oropharynx 26 (29.9%)
Oral cavity 17 (19.4)
Larynx 14 (16%)
Epipharynx 8 (9.2%)
Hypopharynx 7 (8.1%)
Parotid gland 4 (4.6%)
Paranasal sinuses 3 (3.5%)
Skin (BSC, angiosarcoma, melanoma) 2 (2.3%)
Maxilla 2 (2.3%)
Cancer of unknown origin (CUP) 3 (3.5%)
Simultaneous (floor of the mouth/
hypopharynx)
1 (1.2%)
Histological workup
Squamous cell carcinoma 76 (87.4%)
Neuroendocrine carcinoma 2 (2.3%)
Adenocarcinoma 2 (2.3%)
Adenoidcystic carcinoma 2 (2.3%)
Mucoepidermoid carcinoma 1 (1.2%)
Melanoma 1 (1.2%)
Angiosarcoma 1 (1.2%)
Neuroblastoma 1 (1.2%)
Spindle-cell like carcinoma 1 (1.2%)
T-stage:
T1 23 (26.4%)
T2 29 (33.3%)
T3 10 (11.5%)
T4 18 (20.7%)
Not otherwise specified 7 (8.1%)
N-stage:
N0 29 (33.3%)
N1 10 (11.5%)
N2 40 (46%)
N3 3 (3.5%)
Not otherwise specified 5 (5.7%)
TNM staging:
Stage I 6 (6.9%)
Stage II 9 (10.4%)
Stage III 13 (14.9%)
Stage IV 53 (60.9%)
Not otherwise specified 6 (6.9%)
BSC = basal cell carcinoma; CT = computed tomography; FDG =
(18F)fluoro-deoxy-D-glucose; PET = positron emission tomography
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patients was 63.4 ± 12.0 years (range 24–90 years). The in-
dication for PET-CT/MRI was routine follow-up in 89.7%
(n = 78) and re-staging owing to clinically suspected or
histologically confirmed tumour persistence/recurrence in
10.3% (n = 9). Median time between the end of the treat-
ment and PET-CT/MRI examination was 8.8 months (IQR:
3.3–20.5), which coincides with the second follow-up ex-
amination, as mentioned above.
Site of primary tumour, TNM staging, histological
workup and secondary malignancies
Table 1 shows the initial primary tumour sites, overall
TNM staging and histological workup of all patients in-
cluded. In 9/87 patients (10.3%), analysis of patients’
charts revealed a past medical history of a prior malignancy
in the head and neck region, which had already been treated
with curative intent before the appearance of the malig-
nancy of interest.
Treatment protocols
In terms of surgical treatment, 45/87 patients (51.7%) had
surgical resection of the primary tumour, including 22 pa-
tients (25.3%), who received a reconstruction with a local
or free flap. Forty-six patients underwent unilateral or bilat-
eral neck dissection (53.9%). With regard to RT, 79/87 pa-
tients (90.8%) received RT to the primary tumour site and
68/87 patients (78.2%) to the regional neck.
FDG PET-CT and PET-MRI findings
Overall, tumour recurrence, tumour persistence or regional
soft-tissue metastases were found in 14/87 patients
(16.1%). In 4/87 (4.6%) patients local tumour recurrence,
Table 2: Detailed information on all 159 FDG-positive lesions in the
subgroup of disease-free patients.
Sublingual Space, floor of the mouth 29 (18.2%)
Soft palate 22 (13.8%)
Pharyngeal mucosal space 17 (10.7%)
Palatine tonsils, base of the tongue 16 (10.1%)
Oral cavity, tongue 10 (6.3%)
Hypopharynx, aryepiglottic fold 10 (6.3%)
Larynx 6 (3.8%)
Scalene or sternocleidomastoid muscle 7 (4.4%)
Muscles of mastication 5 (3.1%)
Tracheostoma, voice-prosthesis 5 (3.1%)
Epipharynx 3 (1.9%)
Submandibular gland 3 (1.9%)
Mandible 2 (1.3%)
Parotid Space 2 (1.3%)
Thyroid 2 (1.3%)
Upper oesophagus 1 (0.6%)
Hyoid bone 1 (0.6%)
Mastoid process 1 (0.6%)
Styloid process 1 (0.6%)
Cervical lymph nodes
Level I 4 (2.5%)
Level II 9 (5.7%)
Level III 2 (1.3%)
Level IV –
Level V 1 (0.6%)
Total 159 lesions
FDG = (18F)fluoro-deoxy-D-glucose
in 2/87 patients (2.3%) regional tumour recurrence and in
1/87 patient (1.2%) both local and regional tumour recur-
rence was found. In terms of tumour persistence, 3/87 pa-
tients (3.5%) had local and regional persistence and 1/87
patient (1.2%) had regional persistence. Additionally, re-
gional soft-tissue metastases were histologically confirmed
in 3/87 patients (3.5%) after neck dissection. Of note, only
5/14 malignant lesions were detected in clinically asymp-
tomatic patients during routine follow-up diagnostic ima-
ging (two local recurrences, one regional persistence, two
regional soft-tissue metastases) whilst 9/14 patients under-
went PET-CT/MRI owing to clinically or histologically
confirmed persistence/recurrence.
Subset of patients without tumour recurrence /
persistence / soft-tissue metastases
In 73/87 patients (83.9%) imaging as well as clinical
follow-up revealed no tumour persistence, recurrence or
soft-tissue metastases. Of these 73 patients, 65 patients
(89%) did not require further diagnostic procedures apart
from routine clinical examination. In 8/73 (11.7%) patients
with a suspicious lesion in PET-CT and PET-MRI, clinical
examination could not rule out tumour recurrence/persist-
ence and patients then underwent biopsy (n = 6) or fine
needle aspiration (FNA) of regional lymph nodes (n = 2).
Three of these eight patients required multiple biopsies to
exclude recurrence. Finally, the histological and clinical as-
sessment revealed a radiogenic ulcer in the hypopharynx
(n = 1), osteoradionecrosis of the mandible (n = 1), ra-
diogenic chondronecrosis of the corniculate cartilages (n =
1) and unspecific chronic inflammation of the epipharynx,
palatine tonsils and base of the tongue respectively (n = 3).
The FNA due to indistinct FDG-activity in cervical lymph
nodes showed reactive lymphadenopathy in both cases.
A total of 159 FDG-positive lesions with known or un-
known anatomic correlates in the head and neck region
were found in the 73 patients. On average, every FDG PET-
CT and PET-MRI examination revealed 2.1 ± 1.5 FDG-
positive lesions in the head and neck region (range: 0–7).
Of these 159 lesions, 143 lesions (89.9%) were mainly re-
lated to the oral cavity and the oropharynx. Additionally, 16
lesions were related to cervical lymph nodes (10.1%) (table
2).
Review of the most likely aetiology of the lesions showed
physiological FDG uptake in 107 lesions (67.3%), in which
physiological muscle activity, FDG uptake due to lymph-
atic tissue and compensatory FDG uptake after contralater-
al treatment were predominant findings (table 3). Further-
more, 52 FDG-positive lesions (32.7%) were categorised
as inflammatory FDG uptake: post-surgical, inflammatory
uptake (n = 14, 8.8%) vs post-irradiation, inflammatory up-
take (n = 9, 5.7%) vs reactive, not otherwise specified FDG
uptake (n = 29, 18.2%) (table 4). Overall, PET-MRI was
used for twelve lesions, which were mainly related to the
suprahyoid area, to further clarify indistinct FDG accumu-
lation.
Discussion
In this study of HNC patients in post-treatment follow-up,
we demonstrated that non-malignancy-associated FDG-
Original article Swiss Med Wkly. 2015;145:w14116
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positive side findings are very common. Various physiolo-
gical and inflammatory conditions may cause increased
FDG activity, and management of these findings requires
familiarity with patient’s treatment and interdisciplinary
discussion of indistinct lesions. Although the clinical ex-
amination usually clarifies indistinct findings, invasive ex-
Table 3: Detailed information on all FDG-positive lesions considered
physiological.
Floor of the mouth muscles 27 (25.2%)
Soft palate 21 (19.6%)
Muscles of mastication, sternocleidomastoid
muscle, scalene muscle
18 (16.8%)
Pharyngeal mucosal space 16 (15.0%)
Palatine tonsils, Waldeyer ring 8 (7.5%)
Larynx, hypopharynx, upper oesophagus 8 (7.5%)
Salivary glands (compensation due to
contralateral RT)
5 (4.7%)
Tongue (muscular imbalance due to
contralateral resection of the tongue)
4 (3.7%)
Total 107 lesions
FDG = (18F)fluoro-deoxy-D-glucose; RT = radiation therapy
Table 4: Detailed information on all FDG-positive lesions considered
to be due to inflammatory processes.
Unspecific, reactive 29 (55.8%)
Cervical lymph nodes 15
Post-surgical 14 (26.9%)
Tracheostoma, voice prosthesis 5
Oral cavity, tongue 5
Reconstruction of the mandible (synthetic
material)
1
Hypopharynx (post partial laryngo-
pharyngectomy)
1
Mastoid process 1
Shifted submandibular gland due to
reconstruction
1
Post-irradiation 9 (17.3%)
Radiogenic ulcer hypopharynx 1
Osteoradionecrosis (mandible, cricoid, styloid
process)
4
Radiogenic chondronecrosis (corniculate
cartilages)
1
Chronic inflammation (base of the tongue,
epipharynx)
3
Total 52 lesions
FDG = (18F)fluoro-deoxy-D-glucose
Figure 1
(A) Bilateral physiological uptake in the palatine tonsils in a 83-year
old patient with a past medical history of a floor of nose melanoma.
(B) Symmetric increased uptake in the muscles of mastication in
71-year old patient treated for tonsillar carcinoma.
aminations may still be necessary in a considerable number
of patients.
Figure 2
(A) Increased uptake in the right parotid gland in a 56-year old
patient with a past medical history of radical parotidectomy and
adjuvant radiation therapy (RT) on the left side due to a parotid
gland carcinoma. Physiological uptake in the cervical brown fat
tissue and the floor of mouth (FOM) muscles. (B) Increased uptake
in the left paramedian FOM muscles due to muscular dysbalance in
a 69-year old patient with a past medical history of surgical
resection and RT of a right-sided base of the tongue carcinoma
Figure 3
(A) Compensatory uptake in the left vocal cord in a 59-year old
patient with known right unilateral vocal cord immobility due to a
transglottic larynx carcinoma. (B) The corresponding T2-weighted
magnetic resonance imaging examination helps to better delineate
the immobile right vocal cord by providing superior soft-tissue
contrast.
Figure 4
(A) Diffuse bilateral uptake in the thyroid without any morphological
correlate in a 67-year old patient with no clinical, ultrasonographical
or laboratory signs of thyroid dysfunction. (B) The same patient with
corresponding probable reactive lymphadenopathy.
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It is known that PET-CT is more accurate in detecting HNC
recurrence than conventional physical examinations alone
and that therefore negative periodic clinical examinations
may be complemented by FDG PET-CT [8, 15]. As expec-
ted, we observed PET-CT to be a well-established ruling-
out test at the expense of a decreased positive predict-
ive value and specificity [7–9]. However, interpretation of
indistinct FDG-positive findings remains challenging be-
cause of a high number of false-positive lesions and the ne-
cessity for potentially unnecessary and invasive diagnost-
ic investigations. As in previous studies, we found typical
foci of increased FDG uptake [16, 17]. The pharyngeal mu-
cosa frequently causes physiological FDG uptake, hence
the interpretation is usually unproblematic as long as the
uptake is located superficially along the mucosal plane in
linear configuration [18]. The palatine tonsils and other
lymphatic structures of the Waldeyer’s ring typically ex-
Figure 5
(A) Increased focal uptake in the right submandibular gland in a
54-year old patient, who underwent surgical resection and
reconstruction with a pedicled flap owing to a lateral tongue
carcinoma. (B) The corresponding T1–weighted magnetic
resonance imaging helps to delineate the shifted submandibular
gland due to the pectoralis maior myocutaneous flap. (C) Sixty-six
year old patient after segmental mandibular resection, mandibular
reconstruction and implantation of dental implants due to an
anterior floor-of-mouth carcinoma
Figure 6
(A) Increased uptake around inserted voice prosthesis in a 74-year
old patient with a past medical history of total laryngectomy and
radiation therapy (RT) due to a transglottic larynx carcinoma. (B)
Seventy-one year old patient after total laryngectomy, partial
thyroidectomy and RT with increased uptake around the
tracheostoma.
hibit FDG uptake, which most likely reflects a so-called
“physiological inflammation” of the lymphatic tissue due
to confrontation with antigens [18, 19] (fig. 1A). Further-
more, muscles of mastication and intrinsic tongue muscles
were shown to be highly sensitive to exogenous con-
founders such as chewing gum during examination and
therefore a good quality of PET-CT/MRI clearly depends
on the compliance of the patient [20, 21] (fig. 1B). With re-
gard to the floor of mouth (FOM) muscles, a recent study
investigating the effect of a supine versus a sitting position
on physiological FDG accumulation, did not find any alter-
ations and concluded that there is no trick to avoid or re-
duce this kind of disturbing FDG uptake [22]. The correla-
tion between muscular activity and increased FDG uptake
was also shown for the larynx, since talking can cause FDG
uptake in the muscles of phonation as well as in the vo-
cal cords [18, 23]. In terms of FDG uptake in the salivary
glands, the parotid, submandibular and sublingual glands
may all reveal mild to moderate symmetric or asymmetric
uptake, although these findings underlie a marked inter-in-
dividual variability [16, 17]. As there is a close relation-
ship between reduction in FDG uptake into the salivary
glands and increasing doses of RT, we found five patients
with asymmetric salivary gland FDG uptake due to surgical
treatment and RT to the contralateral side [24] (fig. 2A).
Similarly, we observed four patients with asymmetric FDG
uptake in the tongue and FOM as a consequence of mus-
cular imbalance due to contralateral surgical treatment (fig.
2B). Another well-known phenomenon is the increased
Figure 7
(A) Sixty-two year old patient after curative radio-chemotherapy
(RCT) for a supraglottic larynx carcinoma with increased focal
uptake in the left hypopharynx due to a radiogenic ulcer. (B)
Increased focal uptake of the left mandible due to
osteoradionecrosis in a 48-year old patient after curative RCT for
an oropharynx carcinoma (C) Radiogenic chondronecrosis of the
corniculate cartilages in a 59-year old patient after surgical
resection and radiation therapy of a base of tongue carcinoma
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FDG uptake in the contralateral vocal cord if a recurrent
laryngeal nerve palsy is present (fig. 3AB).
Our case series is typical for a tertiary referral centre, with
squamous cell cancer being the most common disease and
the oral cavity / oropharynx being the most common
primary tumour sites. The high proportion of multimodal
treatment protocols in our cohort reflects the fact that most
patients were treated for advanced disease. Our current
practice is to refer patients with small primary tumours
and/or limited regional lymphatic spread for clinical post-
treatment surveillance combined with non-metabolic ima-
ging (CT, US), whereas patients with a large primary tu-
mour (>T2) and/or multiple regional metastases (>N2a)
routinely undergo periodic clinical and PET-CT or now
partly PET-MRI examinations. In this particular subgroup
of patients, as mentioned before, the risk of distant meta-
stases is markedly increased and the whole-body imaging
multimodality provides superior information, when com-
pared with MRI or CT alone. The first post-treatment
baseline PET-CT/MRI should usually be scheduled at least
2 months post-treatment in order to reduce the rate of
false-positive findings due to treatment-related inflammat-
ory changes [25, 26]. In the subgroup of tumour-free pa-
tients, non-malignancy-associated FDG lesions could be
managed by means of clinical examination in 83.9% of all
patients. However, even though the timing for the PET-CT/
MRI examination appears to be appropriate, eight patients
(11.7%) required invasive diagnostic procedures to clarify
indistinct lesions.
One of the most common causes of false-positive FDG
findings in the post-treatment setting is increased FDG up-
take due to benign conditions, such as inflammation, infec-
tions or granulomatous processes [27, 28]. Thus, literally
any inflammatory process in the head and neck region can
cause increased FDG activity [27]. In our study, 32.7% (52/
179) of all FDG-positive lesions were categorised as in-
flammatory FDG uptake, of which a distinct attribution to
an anatomical substrate or a treatment-modality was pos-
sible in only 44.2% (23/52). In 55.8% (29/52), FDG-pos-
itive findings were categorised as reactive, unspecific le-
sions; 15/29 of these lesions were related to cervical lymph
nodes. Thereby, we often assumed multi-aetiological reas-
ons of the FDG-positive lesion with treatment-related and
non-treatment-related contributors [15]. Reactive lymph-
oid hyperplasia arising from inflammatory or infectious
processes frequently causes FDG accumulation in cervical
lymph nodes and often requires a clinical and ultrasono-
graphic re-assessment [29]. However, in our case series
invasive diagnostic procedures such as FNA were neces-
sary in only two patients, indicating that those indistinct le-
sions in cervical lymph nodes are manageable in a reason-
able way. Liu et al. investigated the clinical significance of
diffuse thyroid uptake on PET-CT and usually considered
FDG uptake into the thyroid to be benign and very likely
secondary to thyroiditis and/or hypothyroidism [30] (fig.
4AB).
Typical post-surgical findings were inflammatory FDG up-
take of the tongue and the oral cavity due to transoral sur-
gical resections or a shifted submandibular gland owing to
a pectoralis major myocutaneous flap (fig. 5AB). Patients
after laryngectomy, formation of a tracheostoma and inser-
tion of voice prosthesis frequently showed increased FDG-
activity around the voice prosthesis (fig. 6AB). Implant-
ation of synthetic materials in the head and neck region,
such as a voice prosthesis, can cause increased mucus pro-
duction and tracheal wall damage with accompanying im-
munological cell accumulation and then increased FDG up-
take [31]. Lastly, dental implants or non-removable bridge-
work can also cause artefacts in PET-CT [32]. However, as
it was previously shown by our group, those artefacts might
partly be reduced in PET-MRI [11, 33]. Therefore, PET-
MRI seems to be an additional tool to complement PET-
CT, especially when evaluating the oropharynx and oral
cavity, since synthetic material typically causes artefacts in
this region.
Irradiation-related inflammatory FDG uptake was observed
because of a radiogenic ulcer in the hypopharynx, osteora-
dionecrosis, radiogenic chondronecrosis and chronic mu-
cosal inflammation (fig. 7ABC). The occurrence of false-
positive FDG uptake caused by osteoradionecrosis in HNC
patients after RT is a known difficulty and well-reported
for nasopharyngeal carcinoma [34, 35]. Management of
these lesions is challenging since the clinical examination
can be inconclusive and definitive exclusion of malignancy
often requires multiple biopsies. Re-evaluation by a mul-
tidisciplinary tumour board plays a pivotal role in adequate
management of these challenging patients: surgeons, nuc-
lear medicine physicians, radiation oncologists, oncologists
and pathologists need to carefully review indistinct find-
ings and to determine individual diagnostic algorithms.
Without doubt, biopsy is the gold standard for clarifying in-
distinct FDG-positive lesions. We are aware of the fact that
in this educational study, grading of indistinct lesions as
true positive, true negative, false positive or false negative
findings was mainly based on clinical and radiological ex-
aminations and the further course of disease. However, the
aim of this paper is to support the treating physicians and
to help avoiding potential unnecessary investigations and
complications. As a result of the high number of false-pos-
itive FDG PET-CT findings, invasive procedures should al-
ways be carefully considered in a multidisciplinary setting
and build the last step in the diagnostic algorithm.
Conclusion
Post-treatment follow-up of HNC patients requires famili-
arity with the patient’s medical history, especially in terms
of prior treatment modalities. PET-CT/MRI provides high
sensitivity at the expense of decreased specificity. Hence,
non-malignancy-associated FDG-positive lesions are com-
mon side-findings of routine follow-up examinations.
Awareness of common physiological and treatment-related
confounders of FDG-positivity often allows clarification of
indistinct lesions. However, despite interdisciplinary dis-
cussion of unclear FDG-positive lesions, further invasive
diagnostic procedures are necessary in a non-negligible
proportion of asymptomatic patients.
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Figures (large format)
Figure 1
(A) Bilateral physiological uptake in the palatine tonsils in a 83-year old patient with a past medical history of a floor of nose melanoma. (B)
Symmetric increased uptake in the muscles of mastication in 71-year old patient treated for tonsillar carcinoma.
Figure 2
(A) Increased uptake in the right parotid gland in a 56-year old patient with a past medical history of radical parotidectomy and adjuvant radiation
therapy (RT) on the left side due to a parotid gland carcinoma. Physiological uptake in the cervical brown fat tissue and the floor of mouth (FOM)
muscles. (B) Increased uptake in the left paramedian FOM muscles due to muscular dysbalance in a 69-year old patient with a past medical
history of surgical resection and RT of a right-sided base of the tongue carcinoma
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Figure 3
(A) Compensatory uptake in the left vocal cord in a 59-year old patient with known right unilateral vocal cord immobility due to a transglottic
larynx carcinoma. (B) The corresponding T2-weighted magnetic resonance imaging examination helps to better delineate the immobile right
vocal cord by providing superior soft-tissue contrast.
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Figure 4
(A) Diffuse bilateral uptake in the thyroid without any morphological correlate in a 67-year old patient with no clinical, ultrasonographical or
laboratory signs of thyroid dysfunction. (B) The same patient with corresponding probable reactive lymphadenopathy.
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Figure 5
(A) Increased focal uptake in the right submandibular gland in a 54-year old patient, who underwent surgical resection and reconstruction with a
pedicled flap owing to a lateral tongue carcinoma. (B) The corresponding T1–weighted magnetic resonance imaging helps to delineate the
shifted submandibular gland due to the pectoralis maior myocutaneous flap. (C) Sixty-six year old patient after segmental mandibular resection,
mandibular reconstruction and implantation of dental implants due to an anterior floor-of-mouth carcinoma
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Figure 6
(A) Increased uptake around inserted voice prosthesis in a 74-year old patient with a past medical history of total laryngectomy and radiation
therapy (RT) due to a transglottic larynx carcinoma. (B) Seventy-one year old patient after total laryngectomy, partial thyroidectomy and RT with
increased uptake around the tracheostoma.
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Figure 7
(A) Sixty-two year old patient after curative radio-chemotherapy (RCT) for a supraglottic larynx carcinoma with increased focal uptake in the left
hypopharynx due to a radiogenic ulcer. (B) Increased focal uptake of the left mandible due to osteoradionecrosis in a 48-year old patient after
curative RCT for an oropharynx carcinoma (C) Radiogenic chondronecrosis of the corniculate cartilages in a 59-year old patient after surgical
resection and radiation therapy of a base of tongue carcinoma
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